Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 9/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10017895 | 0.85 | CA1 (0.59) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL13199876 | 0.85 | CA1 (0.59) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL12026537 | 0.85 | CA1 (0.59) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL26109825 | 0.82 | CA1 (0.55) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL26093192 | 0.81 | CA1 (0.57) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL19725934 | 0.79 | CTSK (0.84) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL25819285 | 0.79 | CA1 (0.54) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL17789650 | 0.78 | CA1 (0.52) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL22862910 | 0.77 | CA1 (0.61) | CTSKCA1CA2BTKJAK3 | |
| SCHEMBL21779949 | 0.77 | CTSK (0.59) | CTSKCA1CA2BTKKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | CTSK 1432/4885CA1 4273/4885CA2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.